Gene therapy trial for drug-resistant focal epilepsy
Part of Brain & nervous system clinical trials.
This trial tests a lentiviral gene therapy given for people with focal epilepsy that has not improved with medicines. It’s aimed at helping reduce seizures and is only offered to people who are already being evaluated for brain surgery to remove the seizure-causing area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older) with focal epilepsy that hasn’t responded to medicine
- You’re being considered for brain surgery to remove the seizure area, and your workup started within the last 2 years
- Your brain scans do not show certain blood-vessel problems or cancer where surgery would happen
- You need special brain testing with EEG using a minor procedure (burr hole) to confirm surgery is appropriate
- Doctors must think it’s safe for you to have anesthesia and surgery, and you can follow the plan for 5 years
- You must agree to strong birth control rules if you could become pregnant, and you must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for genetic and chemical clues in people with drug-resistant epilepsy who need brain surgery with electrodes. It aims to help understand why some epilepsies don't respond to medication.
This study tests a personalized, non-invasive brain stimulation method called tDCS for people with drug-resistant epilepsy that starts in one part of the brain. It aims to reduce seizures in those who cannot have surgery or have not been helped by surgery.
This trial uses special MRI scans to create a detailed map of the brain areas causing seizures, helping doctors plan SEEG surgery. It's for people with hard-to-control epilepsy who are already scheduled for SEEG.
This study tests a non-invasive focused ultrasound treatment for people with epilepsy that doesn't respond to medications. The goal is to see if this gentle ultrasound can reduce seizures without surgery.
This trial tests a one-time gene therapy (AMT-260) for adults whose seizures start in one area of the brain (the temporal lobe) and aren't controlled by medication. The goal is to see if it's safe and reduces seizure frequency.
This trial looks at ways to diagnose and treat focal epilepsy that isn't controlled by medications. It includes patients with or without a visible brain lesion on imaging.
Hear when a new Drug Resistant Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.